CureVac (CVAC) Stock Price, News & Analysis

Company Overview

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs. Its RNActive® platform underpins several vaccine candidates, including those targeting seasonal influenza, rabies and other viral pathogens. In oncology, the company is advancing individualized neoantigen vaccines and combination immunotherapies designed to stimulate targeted anti-tumor immune responses. Over the years, CureVac has entered collaborations with pharmaceutical partners to co-develop next-generation mRNA products, most notably a strategic partnership announced in 2021 focused on seasonal influenza vaccines.

CureVac maintains research facilities in Germany and actively engages with the global scientific community through alliances and academic collaborations. The company also operates a presence in the United States to support clinical development and regulatory interactions. Leadership is led by Franz-Werner Haas, who has served as Chief Executive Officer since 2018, guiding CureVac’s transition from pioneering research to commercialization readiness. Supported by an interdisciplinary team of biologists, chemists and clinicians, the company continues to expand its platform capabilities and explore new indications for mRNA therapeutics.

Key Stats

• Today's Range: $5.33 to $5.38
• 50-Day Range: $5.34 to $5.51
• 52-Week Range: $2.37 to $5.72
• Volume: 365,200 shs
• Average Volume: 910,476 shs
• Market Capitalization: $1.20 billion
• P/E Ratio: 5.58
• Dividend Yield: N/A
• Price Target: $6.83
• Consensus Rating: Hold

CureVac Stock Analysis - MarketRank™

CureVac scored higher than 78% of companies evaluated by MarketBeat, and ranked 253rd out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

CureVac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Upside Potential

CureVac has a consensus price target of $6.83, representing about 27.5% upside from its current price of $5.36.

Amount of Analyst Coverage

CureVac has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CureVac is 5.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of CureVac is 5.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.92.

Price to Book Value per Share Ratio

CureVac has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.89% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CureVac has recently increased by 26.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CureVac does not currently pay a dividend.

Dividend Growth

CureVac does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -2.22

Percentage of Shares Shorted

0.89% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CureVac has recently increased by 26.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.82

News Sentiment

CureVac has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CureVac this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for CVAC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CureVac insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 17.26% of the stock of CureVac is held by institutions.

CVAC Stock Analysis - Frequently Asked Questions

How have CVAC shares performed this year?

CureVac's stock was trading at $3.41 at the beginning of the year. Since then, CVAC shares have increased by 57.2% and is now trading at $5.36.

How were CureVac's earnings last quarter?

CureVac N.V. (NASDAQ:CVAC) announced its quarterly earnings data on Thursday, August, 21st. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.15. The business had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 38.21% and a trailing twelve-month return on equity of 29.57%.

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

CureVac's top institutional shareholders include Alpine Associates Management Inc. (0.88%), Qube Research & Technologies Ltd (0.53%), Water Island Capital LLC (0.43%) and JPMorgan Chase & Co. (0.14%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/21/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CVAC
• CIK: 1809122
• Web: www.curevac.com
• Phone: 49-70-71988-30
• Fax: 49-7071-9883
• Employees: 880
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CureVac: $6.83
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +27.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.96
• Trailing P/E Ratio: 5.58
• Forward P/E Ratio: 7.44
• P/E Growth: N/A
• Net Income: $175.50 million
• Net Margins: 38.21%
• Pretax Margin: 42.22%
• Return on Equity: 29.57%
• Return on Assets: 25.41%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 6.17
• Quick Ratio: 6.16

Sales & Book Value

• Annual Sales: $579.18 million
• Price / Sales: 2.08
• Cash Flow: $0.88 per share
• Price / Cash Flow: 6.12
• Book Value: $3.36 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 224,340,000
• Free Float: N/A
• Market Cap: $1.20 billion
• Optionable: Optionable
• Beta: 2.53